A Phase 2/3 interventional study of Venglustat and Placebo in Polycystic Kidney, Autosomal Dominant, sponsored by Genzyme, a Sanofi Company. Terminated at 95 sites in 23 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-02-03.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.
Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 8th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2018, is one of 5 in phase 2/3, and was the 44th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 19–55 · Men only · Healthy volunteers
Kenneth Hallows · Sites in United States
Ages 18–60
Mayo Clinic · Sites in United States
Ages 18–70
Richard Fatica · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, China, United Kingdom
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 18 · Phase 4 2
First in 1998; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 478 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 48 across the 63 interventional studies, 90 across the 22 observational. Of the 59 that completed or were terminated, 34 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 85 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
Sanofi has 5 studies filed under Polycystic Kidney, Autosomal Dominant — fewer than ten, so there is no comparison to draw.
16 of the studies in Polycystic Kidney, Autosomal Dominant with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05193981Mayo ClinicA Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD | 2026-12 |
| NCT05288998Mayo ClinicIntrarenal Microvasculature in ADPKD | 2026-12 |
| NCT06786260Loma Linda UniversityDi-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease | 2026-12 |
| NCT04344769Mayo ClinicCharacterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 2026-12 |
| NCT04630613Mayo ClinicNOX4 and Related Biomarkers in ADPKD | 2026-12 |
Add all 16 to your calendar (.ics) → With an account.
Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage 1) and estimated glomerular filtration rate (eGFR) decline in participants at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2).
Secondary Objectives:
Study duration per participant was 26 months (maximal) that included a screening period of 15 days, run-in period of 2 weeks, a 24-month treatment period, and a follow-up 30 days after final dose of investigational medicinal product (IMP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female adult with ADPKD with age at the time the consent was signed:
Mayo Imaging Classification of ADPKD Class 1C, 1D or 1E**
**Total kidney volume (TKV) had confirmed by a central reader prior to Visit 3.
Estimated glomerular filtration rate between 30 to 89.9 mL/min/1.73 m\^2 during screening period* (CKD-EPI equation) for Stage 2.
*Eligibility would be confirmed by eGFR value from one of the two first pre-randomization eGFR measurements.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants from Stage 1 were randomized to receive 2 capsules of placebo matched to venglustat once daily for treatment period of 24 months.
Drug: Placebo
Participants from Stage 1 were randomized to receive venglustat 8 milligrams (mg) (i.e., 2 capsules of 4 mg) once daily for treatment period of 24 months.
Drug: Venglustat
Participants from Stage 1 were randomized to receive 1 capsule of venglustat 15 mg and 1 capsule of placebo matched to venglustat once daily for treatment period of 24 months.
Drug: Venglustat · Drug: Placebo
Participants from Stage 2 were randomized to receive 1 capsule of placebo matched to venglustat once daily for treatment period of 24 months.
Drug: Placebo
Participants from Stage 2 were randomized to receive 1 capsule of venglustat 15 mg once daily for treatment period of 24 months.
Drug: Venglustat
Pharmaceutical form: capsule; Route of administration: oral
Also known as: GZ402671
Pharmaceutical form: capsule; Route of administration: oral
Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1
Total kidney volume is a measure for assessing disease progression in participants with ADPKD, a prognostic biomarker of renal function decline and progression to end-stage renal disease. Kidney volume was assessed using magnetic resonance imaging (MRI). The annualized slope of change in TKV (in percentage \[%\] per year) in each treatment group was obtained from the back-transformation of the mean slope of log10-transformed TKV obtained from the linear mixed effect model. The model included fix effects of treatment (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per randomization stratification factor: class 1C versus 1D versus 1E), time (as continuous variable in years), treatment \* time interaction and mayo imaging classification \* time interaction and included random intercept and slope.
Time frame: From Baseline to Month 18
Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2
An eGFR was used to measure level of kidney function and determine the stage of kidney disease in ADPKD participants. Baseline eGFR was defined for each participant as the average of eGFR values assessed prior or equal to first dose of study drug or randomization for participants randomized and not exposed. Annualized rate of change in eGFR in each treatment group was obtained from the linear mixed effect model including the fixed categorical effects of treatment group (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per interactive response technology \[IRT\]: 1C, 1D, 1E), time (as continuous variable in years), treatment-by-time, mayo imaging classification-by-time, and included random intercept and slope.
Time frame: From Baseline to Month 24
Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 24: Stage 1
An eGFR was used to measure level of kidney function and determine the stage of kidney disease in ADPKD participants. Baseline eGFR was defined for each participant as the average of eGFR values assessed prior or equal to first dose of study drug or randomization for participants randomized and not exposed. Annualized rate of change in eGFR was obtained from the linear mixed effect model including the fixed categorical effects of treatment group, mayo imaging classification (as per IRT), time (as continuous variable in years), treatment-by-time, mayo imaging classification-by-time, and included random intercept and slope. Due to early termination of study for futility, the two-steps analysis initially planned was not applicable, then the annualized rate of change from baseline in eGFR in Stage 1 population were assessed using all data available up to database lock (i.e., including Month 24 assessment). As this is a slope, it allowed to have more data and to reduce variability.
Time frame: From Baseline to Month 24
Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Combined Stage 1 and Stage 2
Total kidney volume is a measure for assessing disease progression in participants with ADPKD, a prognostic biomarker of renal function decline and progression to end-stage renal disease. Kidney volume was assessed using MRI. The annualized slope of change in TKV (in % per year) in each treatment group was obtained from the back-transformation of the mean slope of log10-transformed TKV obtained from the linear mixed effect model. The model included fix effects of treatment (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per randomization stratification factor: class 1C versus 1D versus 1E), time (as continuous variable in years), treatment \* time interaction and mayo imaging classification \* time interaction and included random intercept and slope.
Time frame: From Baseline to Month 18
Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1
The BPI-SF is a validated, self-administered questionnaire designed to measure a participant's perceived level of pain. The BPI-SF consisted of 15 items that use a numeric rating scale (NRS) to assess pain severity and pain interference in the past 24 hours and the past week. BPI-SF Item 3 asks participants to "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the past 24 hours." The NRS ranged from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicates greater intensity of pain. Least-squares (LS) means, and standard errors (SE) were estimated from mixed-effect model with repeated measures (MMRM) analysis.
Time frame: From Baseline to Month 18
Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2
The BPI-SF is a validated, self-administered questionnaire designed to measure a participant's perceived level of pain. The BPI-SF consisted of 15 items that use a NRS to assess pain severity and pain interference in the past 24 hours and the past week. BPI-SF Item 3 asks participants to "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the past 24 hours." The NRS ranged from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicate greater intensity of pain. LS means and SE were estimated from MMRM analysis.
Time frame: From Baseline to Month 24
Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1
The BFI-SF is a 10-item, validated, self-administered questionnaire that was originally developed to assess fatigue severity. The 10-items were measured on a 0-10 scale, with 0 being 'does not interfere' and 10 being 'completely interferes.' BFI - Item 3 asks participants to 'Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your worst level of fatigue during the past 24 hours. The NRS ranged from 0 (no fatigue) to 10 (worst imaginable fatigue). Higher global scores were associated with more severe fatigue. LS means and SE were estimated from MMRM analysis.
Time frame: From Baseline to Month 18
Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2
The BFI-SF is a 10-item, validated, self-administered questionnaire that was originally developed to assess fatigue severity. The 10-items were measured on a 0-10 scale, with 0 being 'does not interfere' and 10 being 'completely interferes.' BFI - Item 3 asks participants to "Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your worst level of fatigue during the past 24 hours. The NRS ranged from 0 (no fatigue) to 10 (worst imaginable fatigue). Higher global scores were associated with more severe fatigue. LS means and SE were estimated from MMRM analysis.
Time frame: From Baseline to Month 24
Pharmacokinetics: Plasma Concentration of Venglustat: Stage 1
Venglustat plasma concentrations was determined using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Data for this outcome measure was not planned to be collected and analyzed for placebo arm.
Time frame: Day 1: 3 hours Post-Dose, Month 1: Pre-Dose and 3 hours Post-Dose, Month 6: Pre-Dose, Month 18: Pre-Dose
Pharmacokinetics: Plasma Concentration of Venglustat: Stage 2
Venglustat plasma concentrations was determined using a validated LC-MS/MS method. Data for this outcome measure was not planned to be collected and analyzed for placebo arm.
Time frame: Month 1: Pre-dose and 3 hours Post-dose
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Stage 1
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) was any untoward medical occurrence that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. TEAEs were AEs that developed, worsened or became serious during the treatment-emergent (TE) period (defined as the time from the first investigational medicinal product \[IMP\] administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier).
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs): Combined Stage 1 and Stage 2
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAE was any untoward medical occurrence that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. TEAEs were AEs that developed, worsened or became serious during the TE period (defined as the time from the first IMP administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier).
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Number of Participants With Potentially Clinically Significant Abnormalities: Hematology: Combined Stage 1 and Stage 2
Criteria for potentially clinically significant abnormalities: Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) \[Male\]; \<=95 g/L \[Female\]; greater than or equal to (\>=) 185 g/L \[Male\]; \>=165 g/L \[Female\]; Decrease from baseline \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) \[Male\]; \<=0.32 v/v \[Female\]; \>=0.55 v/v \[Male\]; \>=0.5 v/v \[Female\]; Erythrocyte (red blood cells \[RBC\]): \>=6\*10\^12 per liter (/L); Platelet: less than (\<) 100\*10\^9/L; \>=700\*10\^9/L; Leukocyte (white blood cells \[WBC\]): \<3\*10\^9/L \[Non-Black\]; \<2\*10\^9/L \[Black\], \>=16\*10\^9/L; Neutrophils: \<1.5\*10\^9/L \[Non-Black\]; \<1\*10\^9/L \[Black\]; Lymphocytes: greater than (\>) 4\*10\^9/L, Monocytes: \>0.7\*10\^9/L; Basophils: \>0.1\*10\^9/L; and Eosinophils: \>0.5\*10\^9/L or \>upper limit of normal (ULN) (if ULN \>=0.5\*10\^9/L).
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Number of Participants With Potentially Clinically Significant Abnormalities: Clinical Chemistry: Combined Stage 1 and Stage 2
Criteria for potentially clinically significant abnormalities: Glucose: \<=3.9 millimoles per liter (mmol/L) and \<lower limit of normal (LLN): \>=11.1 mmol/L (unfasted); \>=7 mmol/L (fasted); Albumin:\<=25 g/L; Sodium: \<=129 mmol/L; \>=160 mmol/L; Potassium: \<3 mmol/L; \>=5.5 mmol/L; Chloride: \<80 mmol/L, \>115 mmol/L; Creatinine: \>=150 micro millimoles per liter (mcmol/L) (Adults); \>=30% change from Baseline; \>=100% change from Baseline, Urea Nitrogen: \>=17 mmol/L; Alanine Aminotransferase (ALT): \>3 ULN; Aspartate Aminotransferase (AST): \>3 ULN; Alkaline Phosphatase: \>1.5 ULN; Total Bilirubin: \>1.5 ULN, \>2 ULN; ALT \>3 ULN and Bilirubin \>2 ULN; and Direct Bilirubin \>35% Bilirubin and Bilirubin \>1.5 ULN.
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Number of Participants With Potentially and Clinically Significant Abnormalities: Urinalysis: Combined Stage 1 and Stage 2
Criteria for potentially clinically significant abnormalities: Urine pH: \<=4.6 and \>=8.
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Number of Participants With Potentially and Clinically Significant Abnormalities: Vital Signs: Combined Stage 1 and Stage 2
Criteria for potentially clinically significant abnormalities: Sitting Systolic Blood Pressure: \<=95 millimeters of Mercury (mmHg) and decrease from Baseline \>=20 mmHg; \>=160 mmHg and increase from Baseline \>=20 mmHg; Sitting Diastolic Blood Pressure: \<=45 mmHg and decrease from Baseline \>=10 mmHg, \>=110 mmHg and increase from Baseline \>=10 mmHg; Sitting Heart Rate: \<=50 beats/minute and decrease from Baseline \>=20 beats/minute; \>=120 beats/minute and increase from Baseline \>=20 beats/minute; and Weight: \>=5% decrease from Baseline; \>=5% increase from Baseline.
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Number of Participants With Potentially Clinically Significant Abnormalities: Electrocardiogram: Combined Stage 1 and Stage 2
Criteria for potentially clinically significant abnormalities: Heart Rate: \<50 beats/minute; \<50 beats/minute and decrease from Baseline \>=20 beats/minute; \<40 beats/minute; \<40 beats/minute and decrease from Baseline \>=20 beats/min; \<30 beats/minute; \>90 beats/minute; \>90 beats/minute and increase from Baseline \>=20 beats/minute; \>100 beats/minute; \>100 beats/minute and increase from Baseline \>=20 beats/minute; \>120 beats/minute; \>120 beats/minute, increase from Baseline \>=20 beats/minute; PR Interval: \>200 milliseconds (msec); \>200 msec and increase from Baseline \>=25%; \>220 msec, \>240 msec; QRS Interval: \>110 msec; \>110 msec and increase from Baseline \>=25%; \>120 msec; \>120 msec and increase from Baseline \>=25%; QT Interval: \>500 msec; QT corrected for heart rate (QTc) Bazett: \>450 msec; \>480 msec; increase from Baseline (30-60) msec; increase from Baseline \>60 msec; QTc Fridericia: \>450 msec; \>480 msec; increase from Baseline (30-60) msec and increase from Baseline \> 60 msec.
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
Number of Participants With Physical Examination Abnormalities: Combined Stage 1 and Stage 2
Physical examination included: Head, Heart, Lung, Abdomen, Musculo/Skeletal, Skin, and Mental Status. Abnormality in physical examination was based on investigator's discretion. Results are based on the treatment emergent period which was defined as time from the first IMP administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier.
Time frame: Baseline, Month 18, Month 24
Change From Baseline in Beck Depression Inventory-II (BDI-II) Score: Combined Stage 1 and Stage 2
The Beck Depression Inventory-II (BDI-II) is a 21-item questionnaire used to assess depression. Most items are rated on a 4-point scale from 0 to 3, and a few items are rated on a 7-point scale. Individual item scores are added to get a total BDI-II score from 0 to 63. The higher the total score, the more severe the depression, and the lower the total score, the less severe the depression.
Time frame: Baseline, Months 3, 6, 9, 12, 15, 18, 21, and 24, Last on-treatment value up to last IMP + 1 day (anytime during the maximum duration of 25 months)
Number of Participants With Worsening Lens Opacity From Baseline During the Treatment-emergent Period: Combined Stage 1 and Stage 2
Worsening of lens opacity classification system (LOCS) III score or World Health Organization (WHO) grade in nuclear opacification, cortical opacification and posterior subcapsular opacification were assessed for 'Any eye', 'Unilateral' and 'Bilateral' separately. A participant could be counted in all the 3 categories. In each category, the worst case was taken into account. To be evaluable for 'Any', a participant had to have at least one eye evaluable, whereas, for 'Unilateral' and 'Bilateral', a participant had to have both eyes evaluable. Therefore, the sum of 'Unilateral' + 'Bilateral' is not necessarily equal to 'Any' in the below table. The difference observed in 'Nuclear Opacification' in 15 mg group, comes from that 1 participant who had Unilateral worsening at a given visit and a Bilateral worsening at another visit. Therefore, this participant was counted as 'Unilateral', 'Bilateral' and counted only once in 'Any'. Results are based on the TE period.
Time frame: From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier
This study was conducted at 93 sites that enrolled participants in 23 countries. A total of 478 participants were enrolled from 04 October 2018 to 01 June 2021. Study was conducted in 2 stages: Stage 1 and Stage 2.
| Milestone | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg | Stage 2- Placebo | Stage 2- Venglustat 15 mg |
|---|---|---|---|---|---|
| Started | 78 | 78 | 80 | 0 | 0 |
| Completed | 12 | 10 | 12 | 0 | 0 |
| Not completed | 66 | 68 | 68 | 0 | 0 |
| Withdrew: Adverse event | 2 | 2 | 4 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Poor compliance to protocol | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 5 | 7 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 54 | 59 | 56 | 0 | 0 |
| Withdrew: Other-unspecified | 1 | 2 | 0 | 0 | 0 |
| Milestone | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg | Stage 2- Placebo | Stage 2- Venglustat 15 mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 123 | 119 |
| Treated | 0 | 0 | 0 | 122 | 119 |
| Estimated glomerular filtration rate (egfr) between 45 and 89.9 ml/min/1.73 m^2 at screening | 0 | 0 | 0 | 97 | 90 |
| Egfr between 30 and 44.9 ml/min/1.73 m^2 at screening | 0 | 0 | 0 | 25 | 29 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 123 | 119 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 119 | 110 |
| Withdrew: Other-unspecified | 0 | 0 | 0 | 2 | 3 |
| Withdrew: Randomized and not treated | 0 | 0 | 0 | 1 | 0 |
Total kidney volume is a measure for assessing disease progression in participants with ADPKD, a prognostic biomarker of renal function decline and progression to end-stage renal disease. Kidney volume was assessed using magnetic resonance imaging (MRI). The annualized slope of change in TKV (in percentage \[%\] per year) in each treatment group was obtained from the back-transformation of the mean slope of log10-transformed TKV obtained from the linear mixed effect model. The model included fix effects of treatment (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per randomization stratification factor: class 1C versus 1D versus 1E), time (as continuous variable in years), treatment \* time interaction and mayo imaging classification \* time interaction and included random intercept and slope.
| percent change in TKV/year | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg |
|---|---|---|---|
| Annualized Slope of Change in Total Kidney Volume (TKV) From Baseline to Month 18: Stage 1 | 6.35 (5.10 to 7.62) | 7.71 (6.46 to 8.98) | 6.38 (5.11 to 7.66) |
An eGFR was used to measure level of kidney function and determine the stage of kidney disease in ADPKD participants. Baseline eGFR was defined for each participant as the average of eGFR values assessed prior or equal to first dose of study drug or randomization for participants randomized and not exposed. Annualized rate of change in eGFR in each treatment group was obtained from the linear mixed effect model including the fixed categorical effects of treatment group (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per interactive response technology \[IRT\]: 1C, 1D, 1E), time (as continuous variable in years), treatment-by-time, mayo imaging classification-by-time, and included random intercept and slope.
| mL/min/1.73 m^2/year | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) From Baseline to Month 24: Combined Stage 1 and Stage 2 | -2.40 (-3.30 to -1.49) | -4.82 (-5.82 to -3.83) | -4.89 (-5.80 to -3.99) |
An eGFR was used to measure level of kidney function and determine the stage of kidney disease in ADPKD participants. Baseline eGFR was defined for each participant as the average of eGFR values assessed prior or equal to first dose of study drug or randomization for participants randomized and not exposed. Annualized rate of change in eGFR was obtained from the linear mixed effect model including the fixed categorical effects of treatment group, mayo imaging classification (as per IRT), time (as continuous variable in years), treatment-by-time, mayo imaging classification-by-time, and included random intercept and slope. Due to early termination of study for futility, the two-steps analysis initially planned was not applicable, then the annualized rate of change from baseline in eGFR in Stage 1 population were assessed using all data available up to database lock (i.e., including Month 24 assessment). As this is a slope, it allowed to have more data and to reduce variability.
| mL/min/1.73 m^2/year | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg |
|---|---|---|---|
| Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 24: Stage 1 | -3.14 (-4.09 to -2.18) | -4.74 (-5.68 to -3.80) | -4.59 (-5.53 to -3.65) |
Total kidney volume is a measure for assessing disease progression in participants with ADPKD, a prognostic biomarker of renal function decline and progression to end-stage renal disease. Kidney volume was assessed using MRI. The annualized slope of change in TKV (in % per year) in each treatment group was obtained from the back-transformation of the mean slope of log10-transformed TKV obtained from the linear mixed effect model. The model included fix effects of treatment (venglustat 15 mg, venglustat 8 mg or placebo), mayo imaging classification (as per randomization stratification factor: class 1C versus 1D versus 1E), time (as continuous variable in years), treatment \* time interaction and mayo imaging classification \* time interaction and included random intercept and slope.
No measurements were reported for this outcome.
The BPI-SF is a validated, self-administered questionnaire designed to measure a participant's perceived level of pain. The BPI-SF consisted of 15 items that use a numeric rating scale (NRS) to assess pain severity and pain interference in the past 24 hours and the past week. BPI-SF Item 3 asks participants to "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the past 24 hours." The NRS ranged from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicates greater intensity of pain. Least-squares (LS) means, and standard errors (SE) were estimated from mixed-effect model with repeated measures (MMRM) analysis.
| score on a scale | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg |
|---|---|---|---|
| Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | -0.09 ± 0.15 | 0.01 ± 0.17 | -0.35 ± 0.16 |
The BPI-SF is a validated, self-administered questionnaire designed to measure a participant's perceived level of pain. The BPI-SF consisted of 15 items that use a NRS to assess pain severity and pain interference in the past 24 hours and the past week. BPI-SF Item 3 asks participants to "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the past 24 hours." The NRS ranged from 0 (no pain) to 10 (worst imaginable pain), where higher scores indicate greater intensity of pain. LS means and SE were estimated from MMRM analysis.
| score on a scale | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Change in Pain Severity as Measured by Brief Pain Inventory-Short Form (BPI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | -0.20 ± 0.23 | -0.31 ± 0.36 | -0.36 ± 0.23 |
The BFI-SF is a 10-item, validated, self-administered questionnaire that was originally developed to assess fatigue severity. The 10-items were measured on a 0-10 scale, with 0 being 'does not interfere' and 10 being 'completely interferes.' BFI - Item 3 asks participants to 'Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your worst level of fatigue during the past 24 hours. The NRS ranged from 0 (no fatigue) to 10 (worst imaginable fatigue). Higher global scores were associated with more severe fatigue. LS means and SE were estimated from MMRM analysis.
| score on a scale | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage I- Venglustat 15 mg |
|---|---|---|---|
| Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 18: Stage 1 | -0.26 ± 0.23 | -0.10 ± 0.25 | -0.64 ± 0.24 |
The BFI-SF is a 10-item, validated, self-administered questionnaire that was originally developed to assess fatigue severity. The 10-items were measured on a 0-10 scale, with 0 being 'does not interfere' and 10 being 'completely interferes.' BFI - Item 3 asks participants to "Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your worst level of fatigue during the past 24 hours. The NRS ranged from 0 (no fatigue) to 10 (worst imaginable fatigue). Higher global scores were associated with more severe fatigue. LS means and SE were estimated from MMRM analysis.
| score on a scale | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Change in Fatigue Severity as Measured by Brief Fatigue Inventory (BFI-SF)-Item 3 Scale Score From Baseline to Month 24: Combined Stage 1 and Stage 2 | 0.02 ± 0.38 | -0.85 ± 0.55 | -0.51 ± 0.38 |
Venglustat plasma concentrations was determined using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Data for this outcome measure was not planned to be collected and analyzed for placebo arm.
| nanograms per milliliter | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg |
|---|---|---|
| Day 1: 3 hours Post-Dose | 27.8 ± 11.9 | 50.9 ± 22.5 |
| Month 1: Pre-Dose | 54.7 ± 19.2 | 103.9 ± 50.2 |
| Month 1: 3 hours Post-Dose | 82.1 ± 24.7 | 154.6 ± 61.1 |
| Months 6: Pre-Dose | 57.5 ± 23.5 | 106.2 ± 56.3 |
| Months 18: Pre-Dose | 58.3 ± 22.0 | 120.3 ± 73.1 |
Venglustat plasma concentrations was determined using a validated LC-MS/MS method. Data for this outcome measure was not planned to be collected and analyzed for placebo arm.
| nanograms per milliliter | Stage 2- Venglustat 15 mg |
|---|---|
| Month 1: Pre-Dose | 109.3 ± 60.7 |
| Month 1: 3 hours Post-Dose | 163.5 ± 79.7 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) was any untoward medical occurrence that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. TEAEs were AEs that developed, worsened or became serious during the treatment-emergent (TE) period (defined as the time from the first investigational medicinal product \[IMP\] administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier).
| Participants | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg |
|---|---|---|---|
| TEAEs | 62 | 65 | 70 |
| TESAEs | 8 | 15 | 19 |
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAE was any untoward medical occurrence that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. TEAEs were AEs that developed, worsened or became serious during the TE period (defined as the time from the first IMP administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier).
| Participants | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| TEAEs | 128 | 65 | 143 |
| TESAEs | 14 | 15 | 26 |
Criteria for potentially clinically significant abnormalities: Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) \[Male\]; \<=95 g/L \[Female\]; greater than or equal to (\>=) 185 g/L \[Male\]; \>=165 g/L \[Female\]; Decrease from baseline \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) \[Male\]; \<=0.32 v/v \[Female\]; \>=0.55 v/v \[Male\]; \>=0.5 v/v \[Female\]; Erythrocyte (red blood cells \[RBC\]): \>=6\*10\^12 per liter (/L); Platelet: less than (\<) 100\*10\^9/L; \>=700\*10\^9/L; Leukocyte (white blood cells \[WBC\]): \<3\*10\^9/L \[Non-Black\]; \<2\*10\^9/L \[Black\], \>=16\*10\^9/L; Neutrophils: \<1.5\*10\^9/L \[Non-Black\]; \<1\*10\^9/L \[Black\]; Lymphocytes: greater than (\>) 4\*10\^9/L, Monocytes: \>0.7\*10\^9/L; Basophils: \>0.1\*10\^9/L; and Eosinophils: \>0.5\*10\^9/L or \>upper limit of normal (ULN) (if ULN \>=0.5\*10\^9/L).
| Participants | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Hemoglobin: <=115 g/L (Male); <=95 g/L (Female) | 7 | 3 | 5 |
| Hemoglobin: >=185 g/L (Male); >=165 g/L (Female) | 0 | 0 | 0 |
| Hemoglobin: Decrease from baseline >=20 g/L | 4 | 7 | 5 |
| Hematocrit: <=0.37 v/v (Male); <=0.32 v/v (Female) | 40 | 20 | 42 |
| Hematocrit: >=0.55 v/v (Male); >=0.5 v/v (Female) | 0 | 0 | 0 |
| Erythrocyte (RBC): >=6 * 10^12/L | 1 | 0 | 1 |
| Platelet: <100*10^9/L | 0 | 2 | 1 |
| Platelet: >=700*10^9/L | 0 | 0 | 0 |
| Leukocyte (WBC): <3*10^9/L (Non-Black); <2*10^9/L (Black) | 1 | 2 | 4 |
| Leukocyte (WBC): >=16*10^9/L | 0 | 2 | 1 |
| Neutrophils: <1.5*10^9/L (Non-Black); <1*10^9/L (Black) | 1 | 1 | 3 |
| Lymphocytes: >4*10^9/L | 0 | 1 | 0 |
| Monocytes >0.7*10^9/L | 6 | 3 | 7 |
| Basophils: >0.1*10^9/L | 33 | 5 | 8 |
| Eosinophils: >0.5*10^9/L or >ULN | 7 | 2 | 1 |
Criteria for potentially clinically significant abnormalities: Glucose: \<=3.9 millimoles per liter (mmol/L) and \<lower limit of normal (LLN): \>=11.1 mmol/L (unfasted); \>=7 mmol/L (fasted); Albumin:\<=25 g/L; Sodium: \<=129 mmol/L; \>=160 mmol/L; Potassium: \<3 mmol/L; \>=5.5 mmol/L; Chloride: \<80 mmol/L, \>115 mmol/L; Creatinine: \>=150 micro millimoles per liter (mcmol/L) (Adults); \>=30% change from Baseline; \>=100% change from Baseline, Urea Nitrogen: \>=17 mmol/L; Alanine Aminotransferase (ALT): \>3 ULN; Aspartate Aminotransferase (AST): \>3 ULN; Alkaline Phosphatase: \>1.5 ULN; Total Bilirubin: \>1.5 ULN, \>2 ULN; ALT \>3 ULN and Bilirubin \>2 ULN; and Direct Bilirubin \>35% Bilirubin and Bilirubin \>1.5 ULN.
| Participants | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Glucose: <=3.9 mmol/L and <LLN | 17 | 5 | 12 |
| Glucose: >=11.1 mmol/L (unfasted); >=7 mmol/L (fasted) | 10 | 5 | 19 |
| Albumin: <=25 g/L | 0 | 0 | 0 |
| Sodium: <=129 mmol/L | 1 | 0 | 3 |
| Sodium: >=160 mmol/L | 0 | 0 | 0 |
| Potassium: <3 mmol/L | 0 | 1 | 0 |
| Potassium: >=5.5 mmol/L | 5 | 5 | 11 |
| Chloride: <80 mmol/L | 0 | 1 | 0 |
| Chloride: >115 mmol/L | 1 | 0 | 0 |
| Creatinine: >=150 mcmol/L (Adults) | 50 | 21 | 70 |
| Creatinine: >=30% change from Baseline | 12 | 18 | 25 |
| Creatinine: >=100% change from Baseline | 0 | 1 | 4 |
| Urea Nitrogen: >=17 mmol/L | 1 | 0 | 6 |
| ALT: > 3 ULN | 0 | 0 | 0 |
| AST: >3 ULN | 0 | 0 | 0 |
| Alkaline Phosphatase: >1.5 ULN | 3 | 0 | 0 |
| Total Bilirubin: >1.5 ULN | 2 | 0 | 1 |
| Total Bilirubin: >2 ULN | 0 | 0 | 0 |
| ALT >3 ULN and Bilirubin >2 ULN | 0 | 0 | 0 |
| Direct Bilirubin >35% Bilirubin and Bilirubin >1.5 ULN | 2 | 0 | 0 |
Criteria for potentially clinically significant abnormalities: Urine pH: \<=4.6 and \>=8.
| Participants | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Urine pH: <=4.6 | 0 | 0 | 0 |
| Urine pH: >=8 | 0 | 0 | 0 |
Criteria for potentially clinically significant abnormalities: Sitting Systolic Blood Pressure: \<=95 millimeters of Mercury (mmHg) and decrease from Baseline \>=20 mmHg; \>=160 mmHg and increase from Baseline \>=20 mmHg; Sitting Diastolic Blood Pressure: \<=45 mmHg and decrease from Baseline \>=10 mmHg, \>=110 mmHg and increase from Baseline \>=10 mmHg; Sitting Heart Rate: \<=50 beats/minute and decrease from Baseline \>=20 beats/minute; \>=120 beats/minute and increase from Baseline \>=20 beats/minute; and Weight: \>=5% decrease from Baseline; \>=5% increase from Baseline.
| Participants | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Sitting Systolic Blood Pressure: <=95 mmHg and decrease from Baseline >=20 mmHg | 0 | 0 | 1 |
| Sitting Systolic Blood Pressure: >=160 mmHg and increase from Baseline >=20 mmHg | 2 | 3 | 10 |
| Sitting Diastolic Blood Pressure: <= 45 mmHg and decrease from Baseline >=10 mmHg | 0 | 0 | 0 |
| Sitting Diastolic Blood Pressure: >=110 mmHg and increase from Baseline >=10 mmHg | 2 | 4 | 7 |
| Sitting Heart Rate: <=50 beats/min and decrease from Baseline >=20 beats/min | 0 | 2 | 2 |
| Sitting Heart Rate: >=120 beats/min and increase from Baseline >=20 beats/min | 0 | 0 | 0 |
| Weight: >=5% decrease from Baseline | 11 | 4 | 13 |
| Weight: >=5% increase from Baseline | 15 | 9 | 15 |
Criteria for potentially clinically significant abnormalities: Heart Rate: \<50 beats/minute; \<50 beats/minute and decrease from Baseline \>=20 beats/minute; \<40 beats/minute; \<40 beats/minute and decrease from Baseline \>=20 beats/min; \<30 beats/minute; \>90 beats/minute; \>90 beats/minute and increase from Baseline \>=20 beats/minute; \>100 beats/minute; \>100 beats/minute and increase from Baseline \>=20 beats/minute; \>120 beats/minute; \>120 beats/minute, increase from Baseline \>=20 beats/minute; PR Interval: \>200 milliseconds (msec); \>200 msec and increase from Baseline \>=25%; \>220 msec, \>240 msec; QRS Interval: \>110 msec; \>110 msec and increase from Baseline \>=25%; \>120 msec; \>120 msec and increase from Baseline \>=25%; QT Interval: \>500 msec; QT corrected for heart rate (QTc) Bazett: \>450 msec; \>480 msec; increase from Baseline (30-60) msec; increase from Baseline \>60 msec; QTc Fridericia: \>450 msec; \>480 msec; increase from Baseline (30-60) msec and increase from Baseline \> 60 msec.
| Participants | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Heart Rate: <50 beats/min | 7 | 6 | 13 |
| Heart Rate: <50 beats/min and decrease from Baseline >=20 beats/min | 1 | 0 | 1 |
| Heart Rate: <40 beats/min | 0 | 1 | 1 |
| Heart Rate: <40 beats/min and decrease from Baseline >=20 beats/min | 0 | 0 | 0 |
| Heart Rate: <30 beats/min | 0 | 0 | 0 |
| Heart Rate: >90 beats/min | 4 | 2 | 3 |
| Heart Rate: >90 beats/min and increase from Baseline >=20 beats/min | 2 | 2 | 2 |
| Heart Rate: >100 beats/min | 1 | 0 | 2 |
| Heart Rate: >100 beats/min and increase from Baseline >=20 beats/min | 1 | 0 | 1 |
| Heart Rate: >120 beats/min | 0 | 0 | 0 |
| Heart Rate: >120 beats/min and increase from Baseline >=20 beats/min | 0 | 0 | 0 |
| PR Interval: >200 msec | 8 | 2 | 10 |
| PR Interval: >200 msec and increase from Baseline >=25% | 0 | 0 | 0 |
| PR Interval: >220 msec | 1 | 0 | 2 |
| PR Interval: >240 msec | 0 | 0 | 0 |
| QRS Interval: >110 msec | 11 | 4 | 10 |
| QRS Interval: > 110 msec and increase from Baseline >=25% | 0 | 0 | 1 |
| QRS Interval: >120 msec | 2 | 1 | 3 |
| QRS Interval: >120 msec and increase from Baseline >=25% | 0 | 0 | 1 |
| QT Interval: >500 msec | 0 | 0 | 0 |
| QTc Bazett: >450 msec | 5 | 2 | 3 |
| QTc Bazett: >480 msec | 0 | 0 | 0 |
| QTc Bazett: Increase from Baseline [30-60] msec | 13 | 1 | 5 |
| QTc Bazett: Increase from Baseline >60 msec | 0 | 0 | 0 |
| QTc Fridericia: >450 msec | 4 | 1 | 2 |
| QTc Fridericia: >480 msec | 0 | 0 | 0 |
| QTc Fridericia: Increase from Baseline [30-60] msec | 5 | 1 | 3 |
| QTc Fridericia: Increase from Baseline >60 msec | 0 | 0 | 0 |
Physical examination included: Head, Heart, Lung, Abdomen, Musculo/Skeletal, Skin, and Mental Status. Abnormality in physical examination was based on investigator's discretion. Results are based on the treatment emergent period which was defined as time from the first IMP administration up to the last IMP administration in EFC15392 study + 30 days or up to the first visit in LTS15823 study, whichever comes earlier.
| Participants | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Baseline: Head | 1 | 1 | 4 |
| Baseline: Heart | 2 | 1 | 1 |
| Baseline: Lung | 0 | 0 | 0 |
| Baseline: Abdomen | 15 | 12 | 24 |
| Baseline: Musculo/Skeletal | 5 | 1 | 4 |
| Baseline: Skin | 7 | 2 | 3 |
| Baseline: Mental Status | 0 | 0 | 0 |
| Month 18: Head | 0 | 0 | 1 |
| Month 18: Heart | 0 | 0 | 1 |
| Month 18: Lung | 0 | 0 | 0 |
| Month 18: Abdomen | 2 | 1 | 0 |
| Month 18: Musculo/Skeletal | 0 | 0 | 1 |
| Month 18: Skin | 1 | 1 | 0 |
| Month 18: Mental Status | 1 | 0 | 0 |
| Month 24: Head | 0 | 0 | 0 |
| Month 24: Heart | 0 | 0 | 0 |
| Month 24: Lung | 0 | 0 | 0 |
| Month 24: Abdomen | 0 | 0 | 0 |
| Month 24: Musculo/Skeletal | 0 | 0 | 0 |
| Month 24: Skin | 0 | 0 | 0 |
| Month 24: Mental Status | 0 | 0 | 0 |
The Beck Depression Inventory-II (BDI-II) is a 21-item questionnaire used to assess depression. Most items are rated on a 4-point scale from 0 to 3, and a few items are rated on a 7-point scale. Individual item scores are added to get a total BDI-II score from 0 to 63. The higher the total score, the more severe the depression, and the lower the total score, the less severe the depression.
| score on a scale | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Baseline | 4.0 ± 4.7 | 3.0 ± 4.1 | 3.4 ± 4.1 |
| Change at Month 3 | -0.1 ± 4.0 | 0.7 ± 4.0 | 0.7 ± 4.3 |
| Change at Month 6 | -0.6 ± 4.2 | 0.9 ± 4.2 | 0.3 ± 3.9 |
| Change at Month 9 | -0.3 ± 4.8 | 0.1 ± 3.7 | 0.7 ± 4.9 |
| Change at Month 12 | -1.9 ± 3.9 | 0.2 ± 4.7 | 1.5 ± 5.3 |
| Change at Month 15 | -1.5 ± 4.4 | -0.1 ± 4.4 | -0.3 ± 4.0 |
| Change at Month 18 | -1.0 ± 4.9 | 0.5 ± 3.0 | 0.0 ± 3.5 |
| Change at Month 21 | 1.0 ± 9.5 | -0.1 ± 1.3 | 1.1 ± 2.8 |
| Change at Month 24 | -0.3 ± 0.5 | 0.8 ± 2.2 | 0.3 ± 1.7 |
| Change at Last on-treatment value | -0.5 ± 5.1 | 0.1 ± 4.0 | 0.3 ± 4.6 |
Worsening of lens opacity classification system (LOCS) III score or World Health Organization (WHO) grade in nuclear opacification, cortical opacification and posterior subcapsular opacification were assessed for 'Any eye', 'Unilateral' and 'Bilateral' separately. A participant could be counted in all the 3 categories. In each category, the worst case was taken into account. To be evaluable for 'Any', a participant had to have at least one eye evaluable, whereas, for 'Unilateral' and 'Bilateral', a participant had to have both eyes evaluable. Therefore, the sum of 'Unilateral' + 'Bilateral' is not necessarily equal to 'Any' in the below table. The difference observed in 'Nuclear Opacification' in 15 mg group, comes from that 1 participant who had Unilateral worsening at a given visit and a Bilateral worsening at another visit. Therefore, this participant was counted as 'Unilateral', 'Bilateral' and counted only once in 'Any'. Results are based on the TE period.
| Participants | Placebo | Venglustat 8 mg | Venglustat 15 mg |
|---|---|---|---|
| Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Any eye | 8 | 3 | 9 |
| Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Unilateral | 0 | 0 | 4 |
| Worsening of LOCS III score >= 0.5 or WHO grade >= 1.0 in nuclear opacification: Bilateral | 8 | 3 | 6 |
| Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Any eye | 4 | 4 | 4 |
| Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Unilateral | 1 | 0 | 1 |
| Worsening of LOCS III score >= 0.8 or WHO grade >= 1.0 in cortical opacification: Bilateral | 2 | 4 | 3 |
| Worsening of LOCS III score>=0.5 or WHO grade >= 1.0 in posterior subcapsular opacification:Any eye | 2 | 2 | 3 |
| Worsening of LOCS III score>=0.5 or WHO grade >=1.0 in posterior subcapsularopacification:Unilateral | 0 | 1 | 1 |
| Worsening of LOCS III score>=0.5 or WHO grade >=1.0 in posterior subcapsular opacification:Bilateral | 2 | 1 | 2 |
Collected over From the first IMP administration up to the last IMP administration in EFC15392 study + 30 days (i.e., up to 25 months) or up to the first visit in LTS15823 study, whichever comes earlier. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1- Placebo | 0/78 (0%) | 8/78 (10.3%) | 42/78 (53.8%) |
| Stage 1- Venglustat 8 mg | 0/78 (0%) | 15/78 (19.2%) | 46/78 (59%) |
| Stage 1- Venglustat 15 mg | 0/80 (0%) | 19/80 (23.8%) | 48/80 (60%) |
| Stage 2- Placebo | 0/122 (0%) | 6/122 (4.9%) | 32/122 (26.2%) |
| Stage 2- Venglustat 15 mg | 0/119 (0%) | 7/119 (5.9%) | 48/119 (40.3%) |
| Event | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg | Stage 2- Placebo | Stage 2- Venglustat 15 mg |
|---|---|---|---|---|---|
| Renal Cyst InfectionInfections and infestations | 0/78 | 3/78 | 1/80 | 0/122 | 1/119 |
| HaematuriaRenal and urinary disorders | 0/78 | 3/78 | 0/80 | 0/122 | 0/119 |
| Renal Cyst RupturedRenal and urinary disorders | 0/78 | 2/78 | 0/80 | 0/122 | 0/119 |
| AppendicitisInfections and infestations | 1/78 | 1/78 | 2/80 | 0/122 | 0/119 |
| Urinary Tract InfectionInfections and infestations | 1/78 | 0/78 | 2/80 | 0/122 | 0/119 |
| Renal Cyst HaemorrhageRenal and urinary disorders | 0/78 | 0/78 | 0/80 | 0/122 | 2/119 |
| Covid-19Infections and infestations | 0/78 | 0/78 | 0/80 | 2/122 | 0/119 |
| DiverticulitisInfections and infestations | 0/78 | 1/78 | 1/80 | 0/122 | 0/119 |
| Gastroenteritis ViralInfections and infestations | 0/78 | 1/78 | 0/80 | 0/122 | 0/119 |
| InfluenzaInfections and infestations | 0/78 | 1/78 | 0/80 | 0/122 | 0/119 |
| Event | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg | Stage 2- Placebo | Stage 2- Venglustat 15 mg |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 6/78 | 8/78 | 11/80 | 7/122 | 8/119 |
| NasopharyngitisInfections and infestations | 10/78 | 5/78 | 6/80 | 2/122 | 0/119 |
| FatigueGeneral disorders | 1/78 | 4/78 | 9/80 | 3/122 | 2/119 |
| Back PainMusculoskeletal and connective tissue disorders | 8/78 | 6/78 | 8/80 | 5/122 | 2/119 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/78 | 5/78 | 8/80 | 1/122 | 7/119 |
| Urinary Tract InfectionInfections and infestations | 6/78 | 5/78 | 7/80 | 3/122 | 1/119 |
| HypertensionVascular disorders | 2/78 | 5/78 | 7/80 | 4/122 | 4/119 |
| NauseaGastrointestinal disorders | 1/78 | 6/78 | 7/80 | 0/122 | 6/119 |
| Covid-19Infections and infestations | 5/78 | 6/78 | 1/80 | 3/122 | 7/119 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/78 | 4/78 | 6/80 | 4/122 | 6/119 |
Analysis was performed on all participants randomized in the study.
| Age, Continuous(years) | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg | Stage 2- Placebo | Stage 2- Venglustat 15 mg | Total Title |
|---|---|---|---|---|---|---|
| Mean | 42.6 ± 6.0 | 41.7 ± 6.9 | 43.6 ± 5.7 | 41.7 ± 6.9 | 42.1 ± 6.7 | 42.2 ± 6.5 |
| Sex: Female, Male(Participants) | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg | Stage 2- Placebo | Stage 2- Venglustat 15 mg | Total Title |
|---|---|---|---|---|---|---|
| Female | 37 | 31 | 34 | 46 | 48 | 196 |
| Male | 41 | 47 | 46 | 77 | 71 | 282 |
| Race (NIH/OMB)(Participants) | Stage 1- Placebo | Stage 1- Venglustat 8 mg | Stage 1- Venglustat 15 mg | Stage 2- Placebo | Stage 2- Venglustat 15 mg | Total Title |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 27 | 27 | 27 | 52 | 55 | 188 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 1 | 0 | 2 | 0 | 3 |
| White | 48 | 50 | 52 | 66 | 64 | 280 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 2 | 0 | 0 | 2 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Oct 2018 to primary completion in Aug 2021, 33 months.
Results were first posted in Nov 2022, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venglustat
Polycystic Kidney, Autosomal Dominant →